|
|
Article: Waksal Given Seven Years As ImClone Nears Erbitux Filing.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
By the time former ImClone Systems Inc. CEO Samuel Waksal gets out of prison, the cancer drug he helped develop could be on the market.
While a U.S. District Court judge in Manhattan was sentencing Waksal to seven years and three months Tuesday on charges related to insider trading, securities fraud and bank fraud, ImClone and its partner, Bristol-Myers Squibb Co., were no doubt working on the biologics license application for Erbitux (cetuximab) in colorectal cancer.
Waksal, a 55-year-old immunologist, must report to prison July 2. He also has been ordered to pay a little more than $4 million in fines and restitution.
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|